These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38048020)

  • 21. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding barriers to vaccination against invasive meningococcal disease: a survey of the knowledge gap and potential solutions.
    Ballalai I; Dawson R; Horn M; Smith V; Bekkat-Berkani R; Soumahoro L; Vicic N
    Expert Rev Vaccines; 2023; 22(1):457-467. PubMed ID: 37144283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.
    Ciruela P; Martínez A; Izquierdo C; Hernández S; Broner S; Muñoz-Almagro C; Domínguez À;
    Hum Vaccin Immunother; 2013 Mar; 9(3):681-91. PubMed ID: 23303166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries.
    Pinto Cardoso G; Lagrée-Chastan M; Caseris M; Gaudelus J; Haas H; Leroy JP; Bakhache P; Pujol JF; Werner A; Dommergues MA; Pauquet E; Pinquier D
    Front Pediatr; 2022; 10():1000657. PubMed ID: 36507149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.
    Siu T; Tang W; Dawar M; Patrick DM
    Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
    Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global practices of meningococcal vaccine use and impact on invasive disease.
    Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
    Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of Invasive Meningococcal Disease in Colombia: A Retrospective Surveillance Database Analysis.
    Coronell-Rodriguez W; Caceres DC; Cintra O; Guzman-Holst A
    Infect Dis Ther; 2023 Dec; 12(12):2709-2724. PubMed ID: 37966702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014.
    Whittaker R; Dias JG; Ramliden M; Ködmön C; Economopoulou A; Beer N; Pastore Celentano L;
    Vaccine; 2017 Apr; 35(16):2034-2041. PubMed ID: 28314560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines against Meningococcal Diseases.
    Pizza M; Bekkat-Berkani R; Rappuoli R
    Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33022961
    [No Abstract]   [Full Text] [Related]  

  • 35. A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries.
    Valmas C; Arcà E; Hensen M; Rashid H
    Expert Rev Vaccines; 2022 Nov; 21(11):1637-1646. PubMed ID: 36222056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination.
    Burman C; Serra L; Nuttens C; Presa J; Balmer P; York L
    Hum Vaccin Immunother; 2019; 15(2):459-469. PubMed ID: 30273506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive Disease Due to
    Stein-Zamir C; Shoob H; Abramson N; Valinsky L; Jaffe J; Maimoun D; Amit S; Davidovich-Cohen M
    Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
    Huang L; Mauskopf J; Farkouh R; Masaquel C
    Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.